Clinical Trial: A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia

U.S., Feb. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07396870) titled 'A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia' on Feb. 02.

Brief Summary: This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, fixed-dosed phase II clinical study to evaluate the efficacy and safety of LY03020 in chinese acutely psychotic adult subjects with schizophrenia.

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: Schizophrenia

Intervention: DRUG: LY03020

administered orally

DRUG: Placebo

administered orally

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Luye Pharma Group Ltd.

Disclaimer: Curated ...